- Home
- IGMS vs GRAL Comparison
IGMS vs GRAL Comparison
Compare IGMS & GRAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- GRAL
- Stock Information
- Founded
- IGMS 1993
- GRAL 2016
- Country
- IGMS United States
- GRAL United States
- Employees
- IGMS N/A
- GRAL N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- GRAL
- Sector
- IGMS Health Care
- GRAL
- Exchange
- IGMS Nasdaq
- GRAL NYSE
- Market Cap
- IGMS 528.6M
- GRAL 449.6M
- IPO Year
- IGMS 2019
- GRAL N/A
- Fundamental
- Price
- IGMS $7.48
- GRAL $23.62
- Analyst Decision
- IGMS Buy
- GRAL Hold
- Analyst Count
- IGMS 8
- GRAL 2
- Target Price
- IGMS $16.25
- GRAL $16.00
- AVG Volume (30 Days)
- IGMS 213.0K
- GRAL 862.3K
- Earning Date
- IGMS 11-08-2024
- GRAL 11-12-2024
- Dividend Yield
- IGMS N/A
- GRAL N/A
- EPS Growth
- IGMS N/A
- GRAL N/A
- EPS
- IGMS N/A
- GRAL N/A
- Revenue
- IGMS $2,918,000.00
- GRAL $117,669,000.00
- Revenue This Year
- IGMS $386.95
- GRAL $32.48
- Revenue Next Year
- IGMS N/A
- GRAL $14.72
- P/E Ratio
- IGMS N/A
- GRAL N/A
- Revenue Growth
- IGMS 57.64
- GRAL 111.83
- 52 Week Low
- IGMS $6.17
- GRAL $12.33
- 52 Week High
- IGMS $22.50
- GRAL $24.92
- Technical
- Relative Strength Index (RSI)
- IGMS 31.94
- GRAL N/A
- Support Level
- IGMS $7.00
- GRAL N/A
- Resistance Level
- IGMS $10.80
- GRAL N/A
- Average True Range (ATR)
- IGMS 1.02
- GRAL 0.00
- MACD
- IGMS -0.10
- GRAL 0.00
- Stochastic Oscillator
- IGMS 10.39
- GRAL 0.00
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About GRAL GRAIL INC
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages.